TMEM97

Across TCGA pan-cancer cohorts, TMEM97 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM97 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TMEM97 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM97 expression acts as an unfavorable survival marker.

OV, CCRCC, and PDAC are the cancer types where TMEM97 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.813	1.000	.038	4	view →
CCRCC	DFS	Median	II,III,IV	0.234	1.000	.038	4	view →
PDAC	DFS	Median	IV	0.234	0.766	.026	3	view →
UCEC	DFS	Quartile	All	0.836	1.000	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM97–OV (DFS)

Open the OV breakdown →